Friday, September 4, 2026

CYD and H22 Results First Take:

CYD’s FY24 earnings miss reflected ¥200m of one-offs; adjusted net income reached roughly ¥430m and operating cash flow rose 40%.

Portfolio Updates

CYD was sold near $21 versus an $11 entry after exceeding a $19.50 target; proceeds moved to H22.SI, whose CYD stake implies $1.30 NAV and…

Fading a Myopic Sell-Off

Organigram’s shares fell 25% after Q1, despite Motif Labs making OGI Canada’s largest cannabis producer and a top-three player across major…

Publications we follow

Every publication on this site, hand-picked.

69 publications

X accounts we follow

Every account on this site, hand-picked.

55 accounts

Sectors

Ordered by how often our editor reaches for them.